



Clinical trial results:

ESSAI DE PHASE I-II DE RADIOCHIMIOThERAPIE ASSOCIEE AU PANITUMUMAB DANS LE TRAITEMENT DES CARCINOMES EPIDERMOIDES LOCALISES DE L'ANUS

Summary

| | |
|--------------------------|------------------|
| EudraCT number | 2011-005436-26 |
| Trial protocol | FR |
| Global end of trial date | 30 November 2019 |

Results information

| | |
|--------------------------------|--------------|
| Result version number | v1 (current) |
| This version publication date | 23 July 2025 |
| First version publication date | 23 July 2025 |

Trial information

Trial identification

| | |
|-----------------------|----------|
| Sponsor protocol code | FFCD0904 |
|-----------------------|----------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01581840 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Fédération Francophone de Cancérologie Digestive (FFCD) |
| Sponsor organisation address | 7 BD JEANNE D'ARC, Dijon, France, 21079 |
| Public contact | FFCD, Fédération Francophone de Cancérologie Digestive, 33 380668013, marie.moreau@u-bourgogne.fr |
| Scientific contact | FFCD, Fédération Francophone de Cancérologie Digestive, 33 380668013, marie.moreau@u-bourgogne.fr |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 06 December 2018 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 04 December 2018 |
| Global end of trial reached? | Yes |
| Global end of trial date | 30 November 2019 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The primary objective of Phase I is to determine the dose-limiting toxicity (DLT) of 5FU and panitumumab in combination with radiotherapy and mitomycin, and to derive the maximum tolerated dose (MTD) in patients with localized squamous cell carcinoma of the anus.

The primary objective of phase II is to determine the complete response rate 8 weeks after the end of standard radio-chemotherapy treatment (theoretically in week 15) in patients with localized squamous cell carcinoma of the anus, as defined by MRI, endorectal echoendoscopy if necessary, and proctological examination.

Protection of trial subjects:

This research complies with the recommendations of the Declaration of Helsinki (1964) and its amendments (2000), as well as the Public Health Code (Law No. 2004-806 of August 9, 2004 on public health policy).

The investigator undertook to obtain the patient's consent for the clinical and biological studies in writing, after providing adequate information (information sheet and consent forms)

Background therapy: -

Evidence for comparator: -

| | |
|---|------------------|
| Actual start date of recruitment | 05 November 2012 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|------------|
| Country: Number of subjects enrolled | France: 45 |
| Worldwide total number of subjects | 45 |
| EEA total number of subjects | 45 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |

| | |
|----------------------|----|
| Adults (18-64 years) | 31 |
| From 65 to 84 years | 14 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Between January 2016 and November 2017, 45 patients were include to receive Panitumuma plus 5FU plus Mitomycine C plus Radiotherapy

Pre-assignment

Screening details: -

Pre-assignment period milestones

| | |
|------------------------------|----|
| Number of subjects started | 45 |
| Number of subjects completed | 45 |

Period 1

| | |
|------------------------------|----------------------------------|
| Period 1 title | Baseline Period (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

Blinding implementation details:

No blinding

Arms

| | |
|-----------|---|
| Arm title | 5Fu-mitomycine-panitumumab + Radiotherapy |
|-----------|---|

Arm description:

5 FU = 400 mg days 1 to 4 weeks 1, 5 and 8 mitomicyne = 10 mg/m² day 1 week 1 and days 1, weeks 5 and 8 Panitumumab = 3 mg/kg days 1, weeks: 1, 3, 5, 8 and 10
radiochemotherapy: Radiotherapy : PTV1 45 Gy 5 weeks PTV2 20 Gy 2 weeks

| | |
|--|--------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | 5FU |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intravenous use |

Dosage and administration details:

5 FU = 400 mg days 1 to 4 weeks 1, 5 and 8

| | |
|--|--------------------------|
| Investigational medicinal product name | Mitomycin C |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intravenous use |

Dosage and administration details:

10 mg/m² day 1 week 1 and days 1, weeks 5 and 8

| | |
|--|------------------------|
| Investigational medicinal product name | Panitumumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Intravenous use |

Dosage and administration details:

3 mg/kg days 1, weeks: 1, 3, 5, 8 and 10

| | |
|--|-----------------------|
| Investigational medicinal product name | Radiotherapy |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | External use |

Dosage and administration details:

PTV1 45 Gy 5 weeks PTV2 20 Gy 2 weeks

| | |
|---------------------------------------|---|
| Number of subjects in period 1 | 5Fu-mitomycine-panitumumab + Radiotherapy |
| Started | 45 |
| Completed | 45 |

Baseline characteristics

Reporting groups

| | |
|--------------------------------|-----------------|
| Reporting group title | Baseline Period |
| Reporting group description: - | |

| Reporting group values | Baseline Period | Total | |
|--|-----------------|-------|--|
| Number of subjects | 45 | 45 | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 0 | 0 | |
| Infants and toddlers (28 days-23 months) | 0 | 0 | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 0 | 0 | |
| Adults (18-64 years) | 31 | 31 | |
| From 65-84 years | 14 | 14 | |
| 85 years and over | 0 | 0 | |
| Age continuous | | | |
| Units: years | | | |
| median | 60.19 | | |
| inter-quartile range (Q1-Q3) | 56.50 to 67.20 | - | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 36 | 36 | |
| Male | 9 | 9 | |

Subject analysis sets

| | |
|----------------------------|--------------------|
| Subject analysis set title | ITT |
| Subject analysis set type | Intention-to-treat |

Subject analysis set description:

All patients included in the study.

Note: all patients included are part of the per protocol and safety analysis.

| Reporting group values | ITT | | |
|--|-----|--|--|
| Number of subjects | 45 | | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | | |
| Newborns (0-27 days) | 0 | | |
| Infants and toddlers (28 days-23 months) | 0 | | |
| Children (2-11 years) | 0 | | |
| Adolescents (12-17 years) | 0 | | |

| | | | |
|------------------------------|----------------|--|--|
| Adults (18-64 years) | 34 | | |
| From 65-84 years | 11 | | |
| 85 years and over | 0 | | |
| Age continuous | | | |
| Units: years | | | |
| median | 60.19 | | |
| inter-quartile range (Q1-Q3) | 56.50 to 67.20 | | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 36 | | |
| Male | 9 | | |

End points

End points reporting groups

| | |
|---|---|
| Reporting group title | 5Fu-mitomycine-panitumumab + Radiotherapy |
| Reporting group description: | |
| 5 FU = 400 mg days 1 to 4 weeks 1, 5 and 8 mitomycine = 10 mg/m ² day 1 week 1 and days 1, weeks 5 and 8 Panitumumab = 3 mg/kg days 1, weeks: 1, 3, 5, 8 and 10 radiochemotherapy: Radiotherapy : PTV1 45 Gy 5 weeks PTV2 20 Gy 2 weeks | |
| Subject analysis set title | ITT |
| Subject analysis set type | Intention-to-treat |
| Subject analysis set description: | |
| All patients included in the study. | |
| Note: all patients included are part of the per protocol and safety analysis. | |

Primary: Percentage of Patients with Complete Response to Treatment

| | |
|--|---|
| End point title | Percentage of Patients with Complete Response to Treatment ^[1] |
| End point description: | |
| Complete response was defined by the complete disappearance of the tumor on proctological examination and morphological examinations (MRI and/or echo-endoscopy) and the absence of secondary lesion appearance. The responses were validated by an independent committee: <ul style="list-style-type: none">• In the event of a discrepancy between the investigator and the independent committee, the independent committee's response was used;• in case of uncertainty of the investigator on the response, the committee decided on the response in view of the clinical and morphological data; This endpoint was assessed 8 weeks after the end of treatment (week 15). A patient who died (regardless of cause) was considered a failure for the primary endpoint | |
| if 32 or fewer patients have a complete response at 8 weeks (71%), the complete response rate cannot be considered significantly higher than 60%. | |
| if 33 or more patients have a complete response at 8 weeks (73%), the complete response rate is significantly higher than 60%. | |
| End point type | Primary |
| End point timeframe: | |
| 8 weeks evaluations after the end of the treatment by radiochemotherapy | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Given that this is a single-arm study (and therefore not comparative), no inferential statistics were performed.

| End point values | 5Fu-mitomycine-panitumumab + Radiotherapy | | | |
|-----------------------------|---|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 45 | | | |
| Units: Percentage | | | | |
| Complete response | 30 | | | |
| Partial response | 10 | | | |
| Stability | 0 | | | |
| Progression | 4 | | | |
| Death before the evaluation | 1 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Patients With Complete Response to Treatment

| | |
|-----------------|--|
| End point title | Percentage of Patients With Complete Response to Treatment |
|-----------------|--|

End point description:

Complete response was defined by the complete disappearance of the tumor on proctological examination and morphological examinations (MRI and/or echo-endoscopy) and the absence of secondary lesion appearance according to the investigator's opinion

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

16 weeks after the end of the treatment by radiotherapy

| End point values | 5Fu- mitomycine- panitumumab + Radiotherapy | | | |
|-----------------------------|--|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 44 | | | |
| Units: Number | | | | |
| Complete response | 27 | | | |
| Partial response | 9 | | | |
| Stability | 1 | | | |
| Progression | 7 | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: 3 Years Colostomy-free Survival (CFS)

| | |
|-----------------|---------------------------------------|
| End point title | 3 Years Colostomy-free Survival (CFS) |
|-----------------|---------------------------------------|

End point description:

It was defined as the time from inclusion to the date of colostomy or death (from any cause). Patients alive without colostomy were censored at date of last news. If a patient had a shunt colostomy and continuity was restored, the patient was counted among the patients without a colostomy.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

At 3 years after inclusion

| | | | | |
|---|--|--|--|--|
| End point values | 5Fu- mitomycine- panitumumab + Radiotherapy | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 45 | | | |
| Units: Number (95% Confidence Interval) | | | | |
| number (confidence interval 95%) | 68.8 (53.1 to 80.2) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Recurrence-free Survival (RFS) at 3 Years

| | |
|---|---|
| End point title | Recurrence-free Survival (RFS) at 3 Years |
| End point description: It was defined as the time from inclusion to the date of first recurrence (local, regional, metastatic and second anal cancer) or death. Patients alive without recurrence were censored at date of last news | |
| End point type | Secondary |
| End point timeframe: At 3 years after inclusion | |

| | | | | |
|---|--|--|--|--|
| End point values | 5Fu- mitomycine- panitumumab + Radiotherapy | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 45 | | | |
| Units: Number (95% Confidence Interval) | | | | |
| number (confidence interval 95%) | 62.2 (46.5 to 74.6) | | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival (OS) at 12 Months

| | |
|---|------------------------------------|
| End point title | Overall Survival (OS) at 12 Months |
| End point description: The percentage was evaluated at 12 months using the Kaplan Meier estimation. In the safety part all the death collected during the study will be reported. | |
| End point type | Secondary |
| End point timeframe: At 12 months after inclusion | |

| | | | | |
|---|--|--|--|--|
| End point values | 5Fu- mitomycine- panitumumab + Radiotherapy | | | |
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 45 | | | |
| Units: Number (95% Confidence Interval) | | | | |
| number (confidence interval 95%) | 95.6 (83.5 to 99.7) | | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse Events were collected before each cycles of treatment until the end of the treatment period

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|-----------|
| Dictionary name | NCI CTCAE |
|-----------------|-----------|

| | |
|--------------------|-----|
| Dictionary version | 4.0 |
|--------------------|-----|

Reporting groups

| | |
|-----------------------|-------------------|
| Reporting group title | Safety population |
|-----------------------|-------------------|

Reporting group description: -

| Serious adverse events | Safety population | | |
|--|-------------------|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 14 / 45 (31.11%) | | |
| number of deaths (all causes) | 10 | | |
| number of deaths resulting from adverse events | 1 | | |
| General disorders and administration site conditions | | | |
| Fatigue | | | |
| subjects affected / exposed | 2 / 45 (4.44%) | | |
| occurrences causally related to treatment / all | 2 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| General physical health deterioration | | | |
| subjects affected / exposed | 2 / 45 (4.44%) | | |
| occurrences causally related to treatment / all | 2 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Catheter site pain | | | |
| subjects affected / exposed | 1 / 45 (2.22%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Catheter site oedema | | | |
| subjects affected / exposed | 1 / 45 (2.22%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal disorders | | | |

| | | | | |
|---|----------------|--|--|--|
| Abdominal pain | | | | |
| subjects affected / exposed | 1 / 45 (2.22%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Diarrhoea | | | | |
| subjects affected / exposed | 4 / 45 (8.89%) | | | |
| occurrences causally related to treatment / all | 5 / 5 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Nausea | | | | |
| subjects affected / exposed | 1 / 45 (2.22%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Enteritis | | | | |
| subjects affected / exposed | 1 / 45 (2.22%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Small intestinal obstruction | | | | |
| subjects affected / exposed | 1 / 45 (2.22%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 1 / 1 | | | |
| Vomiting | | | | |
| subjects affected / exposed | 1 / 45 (2.22%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Reproductive system and breast disorders | | | | |
| Prostatitis | | | | |
| subjects affected / exposed | 1 / 45 (2.22%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Vaginal fistula | | | | |
| subjects affected / exposed | 1 / 45 (2.22%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |

| | | | |
|---|----------------|--|--|
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 1 / 45 (2.22%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infections and infestations | | | |
| Septic shock | | | |
| subjects affected / exposed | 1 / 45 (2.22%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Orchitis | | | |
| subjects affected / exposed | 1 / 45 (2.22%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Metabolism and nutrition disorders | | | |
| Hypokalaemia | | | |
| subjects affected / exposed | 1 / 45 (2.22%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Decreased appetite | | | |
| subjects affected / exposed | 1 / 45 (2.22%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Safety population | | |
|---|-------------------|--|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 45 / 45 (100.00%) | | |
| Investigations | | | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 5 / 45 (11.11%) | | |
| occurrences (all) | 5 | | |
| Aspartate aminotransferase increased | | | |

| | | | |
|--|------------------|--|--|
| subjects affected / exposed | 5 / 45 (11.11%) | | |
| occurrences (all) | 5 | | |
| Gamma-glutamyltransferase increased | | | |
| subjects affected / exposed | 4 / 45 (8.89%) | | |
| occurrences (all) | 4 | | |
| White blood cell count decreased | | | |
| subjects affected / exposed | 33 / 45 (73.33%) | | |
| occurrences (all) | 33 | | |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 39 / 45 (86.67%) | | |
| occurrences (all) | 39 | | |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 23 / 45 (51.11%) | | |
| occurrences (all) | 23 | | |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 5 / 45 (11.11%) | | |
| occurrences (all) | 5 | | |
| Weight decreased | | | |
| subjects affected / exposed | 28 / 45 (62.22%) | | |
| occurrences (all) | 28 | | |
| Platelet count decreased | | | |
| subjects affected / exposed | 24 / 45 (53.33%) | | |
| occurrences (all) | 24 | | |
| Dehydration | | | |
| subjects affected / exposed | 4 / 45 (8.89%) | | |
| occurrences (all) | 4 | | |
| Injury, poisoning and procedural complications | | | |
| Radiation skin injury | | | |
| subjects affected / exposed | 14 / 45 (31.11%) | | |
| occurrences (all) | 14 | | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 30 / 45 (66.67%) | | |
| occurrences (all) | 30 | | |
| General disorders and administration site conditions | | | |

| | | | |
|-----------------------------|------------------|--|--|
| Fatigue | | | |
| subjects affected / exposed | 35 / 45 (77.78%) | | |
| occurrences (all) | 35 | | |
| Pyrexia | | | |
| subjects affected / exposed | 7 / 45 (15.56%) | | |
| occurrences (all) | 7 | | |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 10 / 45 (22.22%) | | |
| occurrences (all) | 10 | | |
| Proctalgia | | | |
| subjects affected / exposed | 19 / 45 (42.22%) | | |
| occurrences (all) | 19 | | |
| Diarrhoea | | | |
| subjects affected / exposed | 34 / 45 (75.56%) | | |
| occurrences (all) | 34 | | |
| Mucosal inflammation | | | |
| subjects affected / exposed | 15 / 45 (33.33%) | | |
| occurrences (all) | 15 | | |
| Nausea | | | |
| subjects affected / exposed | 24 / 45 (53.33%) | | |
| occurrences (all) | 24 | | |
| Proctitis | | | |
| subjects affected / exposed | 24 / 45 (53.33%) | | |
| occurrences (all) | 24 | | |
| Vomiting | | | |
| subjects affected / exposed | 12 / 45 (26.67%) | | |
| occurrences (all) | 12 | | |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 3 / 45 (6.67%) | | |
| occurrences (all) | 3 | | |
| Anal inflammation | | | |
| subjects affected / exposed | 5 / 45 (11.11%) | | |
| occurrences (all) | 5 | | |
| Constipation | | | |

| | | | |
|---|--|--|--|
| subjects affected / exposed occurrences (all) | 7 / 45 (15.56%) 7 | | |
| Reproductive system and breast disorders Vulvovaginal inflammation subjects affected / exposed occurrences (all) | 22 / 45 (48.89%) 22 | | |
| Skin and subcutaneous tissue disorders Dermatitis acneiform subjects affected / exposed occurrences (all) Skin exfoliation subjects affected / exposed occurrences (all) Erythema subjects affected / exposed occurrences (all) Pruritus subjects affected / exposed occurrences (all) Dry skin subjects affected / exposed occurrences (all) Palmar-plantar erythrodysesthesia syndrome subjects affected / exposed occurrences (all) Ulcer subjects affected / exposed occurrences (all) | 25 / 45 (55.56%) 25 11 / 45 (24.44%) 11 25 / 45 (55.56%) 25 12 / 45 (26.67%) 12 5 / 45 (11.11%) 5 5 / 45 (11.11%) 5 6 / 45 (13.33%) 6 | | |
| Renal and urinary disorders Cystitis subjects affected / exposed occurrences (all) Pollakiuria subjects affected / exposed occurrences (all) Urinary tract pain | 19 / 45 (42.22%) 19 7 / 45 (15.56%) 7 | | |

| | | | |
|--|------------------------|--|--|
| subjects affected / exposed occurrences (all) | 6 / 45 (13.33%) 6 | | |
| Infections and infestations Skin infection subjects affected / exposed occurrences (all) | 3 / 45 (6.67%) 3 | | |
| Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all) | 29 / 45 (64.44%) 29 | | |
| Hypokalaemia subjects affected / exposed occurrences (all) | 9 / 45 (20.00%) 9 | | |
| Hypoalbuminaemia subjects affected / exposed occurrences (all) | 5 / 45 (11.11%) 5 | | |
| Hypocalcaemia subjects affected / exposed occurrences (all) | 7 / 45 (15.56%) 7 | | |
| Hypomagnesaemia subjects affected / exposed occurrences (all) | 4 / 45 (8.89%) 4 | | |
| Hyponatraemia subjects affected / exposed occurrences (all) | 4 / 45 (8.89%) 4 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? Yes

| Date | Interruption | Restart date |
|------------------|--|----------------|
| 09 February 2017 | Enrolment was suspended at the end of stage 1, pending the results of the interim analysis | 01 August 2017 |

Notes:

Limitations and caveats

None reported